Foresite Capital is a healthcare firm that was founded by CEO Jim Tananbaum in 2011. The company has added Dr. Molly He to the team as a venture partner. As Illumina’s former senior director, Molly has more than fifteen years of experience in genomic and pharmaceutical research. According to Jim Tananbaum, Dr. He has a remarkable track record of drug and genomics development and leadership skills that will be an invaluable asset to Foresite.
Foresite’s main headquarters is in San Francisco with an additional office in New York. Foresite prides itself in investing in the most innovative and exciting healthcare companies. The firm invests in enterprises that have late-stage and disruptive products and services in all healthcare sectors. The company has a dynamic and seasoned team that aim at assisting the firm to grow the portfolio of next-generation sequencing. Foresite also provides emerging healthcare providers with growth capital in both public and private sectors.
Dr. Molly He Career Background
At Illumina, Dr. He was in charge of the innovation and improvements of the global protein reagent for the company. Before that, Molly was working at Pacific Biosciences as leader of the protein sciences department. Molly has ten years experience in the pharmaceutical industry and has focused on the design of structurally-based antibodies as well as small molecule drugs that target immune diseases and cancer. Dr. He graduated from Nankai University and the University of California with a Biochemistry Bachelor’s degree and a Ph. D in protein biophysics respectively. She is also an author and holds more than twenty patent applications and published papers in personalized medicine and next-generation sequencing and read full article.
Jim Tananbaum Career Background
Dr. Tananbaum is the founder and CEO of Foresite Capital with approximately 1.1 billion dollars in assets. Jim has over twenty-five years experience where he was the lead investor and manager at Amerigroup, Jazz and Amira Pharmaceuticals. Previously, Dr. Tananbaum held management positions at Theravance and GelTex Pharmaceuticals, which was acquired for 1.6 billion dollars by Genzyme.
From Harvard University Medical School, Jim acquired an M. D and an M.B.A from the prestigious Harvard Business School. He also holds a B.S.E.E and B.S from Yale University. Jim is a newcomer to the Forbes Midas List that features top hundred investors and learn more about Jim.
More visit: https://www.facebook.com/foresitecapital